|
PresentID: SAT0360 原文 TANAR- A ETANERCEPT BIOSIMILAR IS AS EFFECTIVE AS ADALIMUMAB AND INFLIXIMAB IN ACOHORT OF REAL-LIFE OF PATIENTS WITH RHEUMATOID ARTHRITIS P. Santos-Moreno1,*, G.Saavedra-Martinez2, L. Villarreal3, D. Gomez1, J. Bello-Gualtero1, V. Giraldo4,P. Martinez4, A. Sanchez4, M. Sanchez4, E. Uribe4, M. Boon4 1Rheumatology, 2Epidemiology,3Psychology, 4Internal medicine, Biomab, Center For Rheumatoid Arthritis,Bogota, Bogota, Colombia Background: Clinical response in patients with rheumatoid arthritis (RA) using biologics is well-known. However, there is no direct comparison between biologics in cohorts of patients with RA inreal-life settings, which could have implications in treatment decisions andhealth economics. Objectives: The aim of this study was to describe a direct comparison in effectiveness between two classical antiTNF biologics (Adalimumab, Infliximab) and one Etanercept biosimilar in patients with long-standing RA in a cohort of real-life. Methods: A descriptive cross-sectionalstudy was performed. Were included 158 patients with at least 6 visits to rheumatologist in last 24 months in a specialized in RA center. Clinical follow-up was designed by the authors according to DAS28 as follows: every 3-5weeks (DAS28 > 5.1), every 7-9 weeks (DAS28 ≥ 3.1 and ≤ 5.1), and every11-13 weeks (DAS28 < 3.1). Therapy had to be adjusted with DAS28 > 3.2 unless patient′s conditions don’t permit it; we considered this follow-up type as implementation of a T2T strategy. We divided patients in two groups:remission-low disease activity (Rem/LDA) patients and moderate-severe diseaseactivity (MDA/ SDA) patients and the aim of the study was to look at what percentage of patients who were MDA/SDA disease activity reached a low disease activity or remission. 158 patients with RA and using Adalimumab, Infliximab and Etanerceptbiosimilar (Etanar? CP Guojian Pharmaceutical Co Ltd, China) were involved. The Etanercept biosimilar was approved for using in Colombiasince 2007. Descriptive epidemiology was done, the medians were analyzed usingt-Student assuming normality for DAS28 distribution and disease activity was analyzed using Pearson′s statistics. Results: 158 patients were included inthis study, 125 (79.1%) women and 33 (20.9%) men. Average age was 59 +/- 10 y/owith disease duration of 11 years (0.5-47). 158 patients with diagnosis of RA using Adalimumab, Etanercept and Infliximab were involved: Adalimumab 61 (38.6%), Etanercept 25 mg 62 (39.2%), and Infliximab35 (22.2%). At 24 months was observed an increase in percentage of patients in remission and a decrease in percentage of patients in MDA/SDA disease activity statistically significant. for Adalimumab at beginning DAS28-3.6 and 24months later 2.6; for Etanercept biosimilar at beginning DAS28-3.6 and 24months later 2.6 and for Infliximab at beginnng DAS28-3.6 and 24 months later 2.6.There were not statistically significant differences between analyzed biologics. On the other hand, there were fewer adverse events with Etanercept-biosimilar than Adalimumab and Infliximab; it was statistically significant. Conclusions: This study shows that the Etanercept biosimilar is as effective as 2 othertraditional anti-TNF biological for disease activity control in patients with rheumatoid arthritis in a real-life setting with fewer adverse events, which could have implications in treatment decisions and health economics. On the other hand the study proves effectiveness of implementation of a T2T strategyin patients with RA. 译文 背景：生物制剂治疗RA的临床疗效众所周知。但尚无现实世界直接对比生物制剂治疗RA的疗效研究，这样的研究可以影响治疗选择及健康经济学。 目的：在现实队列研究中直接比较两种经典生物制剂（阿达木单抗、英夫利西单抗）与一种依那西普生物类似药（益赛普）治疗长病程RA的疗效。 方法：该研究为横断面研究。研究纳入158例到专科RA治疗中心至少随访6次的患者。随访频率由研究者者根据患者DAS28情况而定：若DAS28＞5.1则每3~5周随访一次，若DSA28≥3.1且≤5.1则每7~9周随访一次，若DAS28＜3.1 则每11~13周随访一次。除外患者条件不允许，若DAS28 ＞3.2则需调整治疗方案，我们将这种随访看作是达标治疗策略的一种体现。患者分为2组，临床缓解-低疾病活动度组（Rem/LDA），和中、高疾病活动度组（MDA/SDA） 。本研究旨在探讨MDA/SDA组患者达到Rem/LDA的患者比例。158例RA患者分别使用阿达木单抗、英夫利西单抗和益赛普。2007年益赛普在哥伦比亚获批上市（在当地的商品名为Etanar?）。本研究总结了描述性流行病学数据，当DAS28符合正态分布则采用t检验，应用Pearson检验分析疾病活动度。 结果：研究纳入158例患者，女性125例(79.1%)，男性33 例(20.9%)。平均年龄59±10 岁，病程11年(0.5-47)。158 例确诊RA患者分别接受阿达木单抗、英夫利西单抗和益赛普治疗，其中61 人(38.6%)使用阿达木单抗, 62例应用益赛普(25mg，39.2%)，英夫利西单抗 35例 (22.2%)。24个月时，缓解患者比例增加，而MDA/SDA患者比例有所下降， 均达到统计学显著意义。三种TNF拮抗剂的初始DAS28均为3.6，24个月时均为为2.6，3种生物制剂之间无明显差异。另一方面，益赛普组的不良事件发生率显著低于阿达木单抗组和英夫利西单抗组。 结论：本研究显示，在真实世界中，益赛普与其它两种传统TNF拮抗剂治疗RA的疗效无显著差异，且不良事件较少。该结论可能对未来治疗决策和健康经济学有借鉴意义。同时，本研究表明在真实世界中对RA患者执行目标治疗策略是有效的。 |
|
|
